<DOC>
	<DOCNO>NCT00642733</DOCNO>
	<brief_summary>This single arm study ass efficacy safety Tarceva + gemcitabine patient locally advance , unresectable metastatic pancreatic cancer . Patients receive Tarceva 100mg po daily , combination gemcitabine 1000mg/m2 iv weekly 8 week , follow weekly 3 week 4 week cycle . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study First Line Treatment With Tarceva ( Erlotinib ) Combination With Gemcitabine Patients With Locally Advanced Unresectable Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; pancreatic cancer , surgically unresectable metastasis ; previous chemotherapy ( except concomitant radiotherapy ) ; ECOG 02. pancreatic cancer without histologic cytologic confirmation ; surgical resection possible ; previous chemotherapy concomitant radiotherapy ; ECOG 34 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>